Results demonstrated that CXCR6 had more effective anti‐tumour responses with prolonged tumour rejection occurring in 33.3% of mice, whereas mice treated with CXCR3 or CCR4 had only 16.7%–0% prolonged tumour rejection. This evidence concerns the gene CXCR3 and neoplasm.